Latex particle agglutination (LPA) testing for antigen to group B streptococcus (GBS) has been useful in the diagnosis of GBS sepsis in newborns. However, recent reports have demonstrated that the sensitivity of LPA assays may be as low as 27 to 54%. The purposes of the present study were to directly compare the abilities of four urine antigen assays to detect GBS antigen with clinical urine samples from neonates with GBS bacteremia and to evaluate the effect of the urine concentration on the sensitivities and specificities of these assays. Urine samples were collected serially from neonates with blood cultures positive for GBS or on admission from healthy full-term infants. One milliliter of urine was removed, and the remainder was concentrated to a volume of 1 ml. Unconcentrated samples were serially diluted with normal saline and were assayed to determine the highest dilution which would produce a positive test result. The Wellcogen, Bactigen, and Directigen LPA tests and ICON immunoassay were directly compared by using concentrated and unconcentrated urine specimens and urine specimens with known titers. A total of 94 urine specimens, including 61 concentrated and 75 unconcentrated specimens, from bacteremic infants were available for sensitivity testing, and 220 urine specimens from uninfected infants were available for specificity testing. There were significant differences in sensitivity among the four assays when they were performed on concentrated urine specimens, as follows: Directigen, 98%; Bactigen, 92%; ICON, 89%; Wellcogen, 68%. When the assays were performed on unconcentrated urine specimens, the Directigen (84%) and Bactigen (76%) assays were each significantly more sensitive than the ICON (59%) or Wellcogen (43%) assay. All four assays were significantly more sensitive in detecting GBS antigen in concentrated than in unconcentrated urine. The Directigen assay detected antigen in higher dilutions (geometric mean titer, 1:5) than the ICON (1:3), Bactigen (1:2), or Wellcogen (1:1) assay. The specificity was 99.5% for all four assays when concentrated urine was used and for the Bactigen, Directigen, and ICON assays when unconcentrated urine was used; the Wellcogen assay was 100% specific when unconcentrated urine was used. We conclude that there are significant differences in sensitivity but not specificity among the commercially available assays for the detection of GBS antigenuria when concentrated and unconcentrated urine specimens are tested. These differences in sensitivity may affect the abilities of clinicians to accurately diagnose GBS sepsis before culture results are available.
The group B beta-hemolytic streptococci (GBS) are the most common organisms associated with bacteremia in neonates, with an incidence of infection of 1.3 to 3 per 1,000 live births (3). The incidence of infection has not decreased over the past 20 years, but there has been a dramatic improvement in birth weight-specific survival, with overall survival currently being 86% (27) . The decline in the mortality rate is thought to be related to several factors, including improved neonatal intensive care, the use of intrapartum antibiotics, and earlier recognition of GBS sepsis (27) .
Early diagnosis of GBS disease remains difficult, since symptoms are very nonspecific and some neonates may be asymptomatic (27) . The complete blood cell count and differential have been advocated as useful screening tools for the diagnosis of early-onset sepsis (19) . However, the complete blood cell count has poor sensitivity and specificity when it is used early in the evaluation for sepsis at a time when the decision to start antibiotics is most crucial (13) .
Since 1979, latex particle agglutination (LPA) testing has been used as a tool in the evaluation of newborns for GBS sepsis (10) . Detection of bacterial antigen in a sterile body fluid provides for an early presumptive diagnosis of infection pending confirmation by bacterial isolation and identification from culture. The LPA assay is useful as a screening tool because it is inexpensive, is easy to perform, and provides useful information in a timely fashion, before the results of a culture are available. The assay is also a useful adjunct in the evaluation of infants when the reliability of standard blood cultures has been compromised. It may be difficult to diagnose early-onset sepsis in infants whose mothers have received antibiotics in the intrapartum period, since the infant's blood culture may be sterile (8) .
Use of an assay with the highest sensitivity will provide the clinician with the most helpful information in evaluating a newborn for infection. There are three commercially available LPA assays and one enzyme immunoassay for the diagnosis of GBS infection in neonates. There is a wide variation in the reported sensitivities of these commercially available antigen assays. The assay which has been evaluated the most is the Wellcogen Strep B LPA assay. The sensitivity of this assay was initially reported to range from 88 to 100% (4, 11, 15, 17) .
Several recent reports, however, have noted that the sensitivities of LPA assays may be as low as 27 to 54% (6, 14) .
The specificity of urine LPA assays has ranged from 81 to 100% in previous studies (4, 9, 11, 15, 17, 21) . Two recent studies have arrived at conflicting conclusions with respect to the effect of mucocutaneous colonization with GBS on the production of false-positive urine antigen tests (16, 24) . Both of these studies evaluated only the Wellcogen Strep B LPA assay.
There have been no direct comparisons of these four assays by using clinical specimens from healthy infants or from infants with GBS bacteremia. The purpose of the study described here was to directly compare the abilities of these four assays to detect GBS antigen by using multiple urine samples from neonates with GBS bacteremia and to evaluate the effect of urine concentration on the sensitivity and specificity of each of these assays.
(Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., 17 to 20 October 1993.)
MATERIALS AND METHODS
Sensitivity. Infants were identified as participants in the study prospectively on the basis of clinical symptoms, history of maternal GBS exposure, or a positive urine LPA test performed for clinical indications. Only infants with a positive blood culture for GBS were included in the study. This study was approved by the institutional review boards of the participating centers, and informed consent was obtained prior to inclusion in the study.
Urine specimens were collected on a daily basis until 14 days of age and then on a weekly or biweekly basis as available until two consecutive negative specimens were obtained. Urine was collected from an indwelling bladder catheter if one was in place or from a urine bag by standard aseptic technique. When urine bags were used, the perineum was cleansed with povidone-iodine (Betadine), allowed to dry for 30 s, and wiped with alcohol, and then the urine bag (U-Bag; Hollister, Inc., Libertyville, Ill.) was applied to the perineum. Bags were checked frequently and were removed when 5 to 10 ml of urine had been collected or after a maximum of 6 h. Urine was placed in a sterile specimen container and was stored for up to 72 h at 4ЊC until it was processed.
Urine was streaked onto Trypticase soy agar with 5% sheep blood (TSA II; BBL Microbiology Systems, Cockeysville, Md.), and the plate was incubated at 37ЊC for up to 48 h for culture. Isolates were identified by standard microbiologic techniques. Urine specimens which were positive for GBS on culture were eliminated from the study to avoid the potential effect of surface contamination on urine collected in urine bags (24) . Urine was then prepared for antigen testing by the following protocol or was frozen at Ϫ70ЊC until batch testing of the urine was performed.
If the specimen volume was adequate, 1 ml of urine was removed to be used as the unconcentrated specimen and the remaining volume was concentrated up to 25 times to a volume of 1 ml by using the Minicon B-15 Concentrator (Amicon Corp., Lexington, Mass.). If the specimen volume was inadequate to permit concentration, only the unconcentrated specimen was included in the study. Concentrated and unconcentrated specimens were both heated at 100ЊC for 5 min, centrifuged at 2,000 ϫ g for 10 min, and then cooled to room temperature. Serial twofold dilutions with normal saline (1) were then prepared from the unconcentrated specimen to find the highest titer which produced a positive test result for each individual assay. Assays were performed on serial dilutions until two consecutive dilutions were negative. The maximum titer was considered to be the last dilution at which the antigen assay was positive.
Concentrated and unconcentrated urine specimens and urine specimens whose titers were known (titered urine specimens) were tested by using multiple lots of the following assays For the purpose of calculating sensitivity in the present study, a positive test result was defined as a test on a urine specimen collected at any time from a patient with GBS bacteremia for which any one of the four assays was positive and the simultaneous urine culture was negative for GBS. Conversely, a negative test was defined as a test on a urine specimen collected from a patient with GBS bacteremia 24 h or more after obtaining a positive blood culture for which all four assays were negative. The LPA assays were considered positive if any degree of agglutination was present; the enzyme immunoassay was considered positive if an appropriate color change was observed. The positive and negative controls provided by the manufacturers were run simultaneously with each specimen.
Sensitivity was calculated for each assay as the number of positive tests divided by the total number of concentrated or unconcentrated specimens available for analysis. The sensitivity of each assay with concentrated urine versus that with unconcentrated urine was compared by the 2 test. For both the concentrated and unconcentrated urine specimens, the sensitivities of all four assays were compared by the nonparametric Cochran Q test, with pairwise comparisons made by McNemars' test for paired data. Analysis of variance for repeated measures with the Scheffé post hoc F test for multiple comparisons was used to compare the performance of the assays on titered, unconcentrated urine; the geometric mean titer was calculated from a log transformation of the titer data. Significance was accepted for P Յ 0.05.
Specificity. All asymptomatic full-term infants born from February to October 1992 were eligible for inclusion in the specificity phase of the study. Only infants born on Sunday through Thursday were enrolled in order to allow for processing of specimens for culture within 24 h of specimen collection. After admission to the newborn nursery, specimens for culture were collected from the following five sites by using a rayon-tip swab with Stuart's modified medium (Precision Culture Collection and Transport System; Precision Dynamics Corporation, San Fernando, Calif.): nares, external auditory canal, rectum, penis or vagina, and gastric aspirate. Specimens for culture were refrigerated at 4ЊC for less than 24 h until they were processed. Culturettes were inoculated directly onto sheep blood agar and also in selective broth medium (Todd-Hewitt broth [Difco Laboratories, Detroit, Mich.] with 5% sheep blood, 8 g of gentamicin per ml, and 15 g of nalidixic acid per ml), and the plates were incubated for 24 h at 37ЊC. Specimens in the selective broth medium were then streaked onto blood agar plates and were incubated for an additional 24 to 48 h at 37ЊC. Betahemolytic colonies were identified with the Streptex Test kit (Wellcome Diagnostics, Research Triangle Park, N.C.).
After the infant was bathed, urine was collected with a urine bag by aseptic technique as described above. Urine was refrigerated at 4ЊC for less than 24 h until it was processed. Urine was streaked onto Trypticase soy agar with 5% sheep blood, and the plate was incubated at 37ЊC for up to 48 h. Isolates were identified by standard microbiologic techniques.
Urine was then prepared for antigen testing by the protocol outlined above. Testing was performed on concentrated and unconcentrated urine specimens by the Wellcogen, Bactigen, Directigen, and ICON assays. Assays were performed by a single medical technologist (D.M.H.) according to the manufacturers' specifications. The LPA assays were considered positive if any degree of agglutination was present; the enzyme immunoassay was considered positive if an appropriate color change was observed. The positive and negative controls provided by the manufacturers were run simultaneously with each specimen.
Infants who developed symptoms suggestive of sepsis were evaluated and tested by the physicians in the nursery irrespective of their participation in the study. To ensure that only healthy, asymptomatic infants were included in the study, the infants who were evaluated and/or treated for suspected sepsis were removed from the study and subsequent data analysis. At the time that the study was performed, healthy infants were routinely observed for 72 h before discharge from the nursery. Infants included in the data analysis remained healthy and asymptomatic prior to discharge and were therefore assumed to be uninfected. For the purpose of calculating specificity in the study, a negative test result was defined as a test on a urine specimen collected within 12 h of birth from a healthy full-term infant for which the antigen assay was negative. Specificity was calculated for each assay as the number of negative tests divided by the total number of specimens available for analysis.
RESULTS

Sensitivity.
Twelve patients with blood cultures positive for GBS were eligible for the study. Consent was refused for one patient. The characteristics of the remaining 11 patients are given in Table 1 . The estimated gestational ages of the patients ranged from 29 to 42 weeks; two patients were preterm (Ͻ37 weeks). The birth weights of the patients ranged from 1,580 to 4,020 g. There were four male and seven female patients. For seven patients there was a history of prolonged rupture of membranes (Ͼ12 h), and for the mothers of six patients there was a history of fever. Seven patients had respiratory distress, and five required treatment for hypovolemia. The mothers of four patients were treated for chorioamnionitis, including two who were treated with ampicillin and gentamicin 1 to 2 h prior to delivery.
Ninety-four urine specimens were collected from the 11 patients. The patient's age at the time of collection of the first urine specimen, age at the time of collection of the last positive urine specimen, and number of positive urine specimens are given in Table 1 . The age at the time that the first urine specimen was collected ranged from 12 to 86 h. Antigen was not detectable in the urine of the two patients whose first urine specimens were collected at 64 and 86 h of life. Their urine specimens were considered negative by definition because of the elapsed time between the collection of the positive blood culture and the collection of the urine specimen and were thus not included in the analysis. The duration of antigenuria ranged from 1 to 120 days for those patients in whom antigenuria was detectable. The number of positive urine specimens ranged from 0 to 21, with antigen being detected in more than one urine specimen from eight patients.
Serotyping was performed to document the fact that a wide range of serotypes was included in the study. Of nine isolates available for serotyping, three each were of serotypes Ia/c, III, and V (Table 1) . Serotype V was recently recognized as a cause of invasive GBS disease in neonates (12, 22) .
Of the 94 urine specimens collected, 61 concentrated and 75 unconcentrated urine specimens were available for analysis. The quantity of specimen available for testing was insufficient to perform testing on 24 concentrated and 10 unconcentrated urine specimens. In addition, no antigen detectable by any of the four assays was present in nine specimens; these specimens were categorized as true negatives by definition and were not included in the sensitivity calculations. No urine cultures were positive for GBS. Fifteen of the 94 urine cultures were positive for organisms other than GBS (Staphylococcus aureus, Enterococcus faecalis, Klebsiella pneumoniae, Escherichia coli, viridans group streptococcus, coagulase-negative staphylococcus, corynebacterium, and yeasts). Of these, only S. aureus (11) and E. faecalis (18) have previously been associated with false-positive urine antigen tests for GBS. However, there was no consistent pattern of contamination in any one patient by any one specific bacterial contaminant in our study. Table 2 compares the sensitivities of the four assays by using concentrated and unconcentrated urine. All four assays were significantly more sensitive with concentrated urine ( 2 ; P Յ 0.01). There was a significant difference in the sensitivities of the four assays when either concentrated or unconcentrated urine was used (nonparametric Cochran Q test; P Ͻ 0.0001). Table 3 shows the pairwise comparisons of the assays with both concentrated and unconcentrated urine. The Directigen, Bactigen, and ICON assays were each significantly more sensitive than the Wellcogen assay in detecting GBS antigen in either concentrated or unconcentrated urine (McNemars' test; P Ͻ 0.005). In addition, the Directigen and Bactigen assays were each significantly more sensitive than the ICON assay in detecting GBS antigen in unconcentrated urine (McNemars' test; P Ͻ 0.005). There were no significant differences in sensitivity between the Bactigen and Directigen assays with either concentrated or unconcentrated urine. Table 4 compares the abilities of the antigen assays to detect antigen in titered, unconcentrated urine specimens. The geometric mean titer at which antigen remained detectable ranged from 1:1 (no dilution of an unconcentrated specimen) for the Wellcogen assay to 1:5 for the Directigen assay. These pairwise differences in the abilities of the assays to detect maximally dilute urine were all significant (analysis of variance for repeated measures, P ϭ 0.0001; Scheffé post hoc F test for multiple comparisons, P Ͻ 0.05). The maximum titer at which the unconcentrated urine remained positive ranged from 1:32 for the Wellcogen assay to 1:512 for the Directigen assay.
Specificity. Urine was obtained from 240 infants. Twenty infants (8.3%) were subsequently evaluated for sepsis because of symptoms and/or maternal risk factors at the discretion of the nursery physicians. These infants were removed from the data analysis. Of the 220 remaining infants, 115 (52.3%) were male and 105 (47.7%) were female. The mean Ϯ standard deviation birth weight was 3,549 Ϯ 518 g, and the mean estimated gestational age was 39.3 Ϯ 1.4 weeks. Urine was collected at 9.4 Ϯ 2.6 h of life after the urine bag had been 
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on June 20, 2017 by guest http://jcm.asm.org/ applied for 4.4 Ϯ 1.9 h. For 5 of the 220 infants (2.3%) urine or surface specimen cultures were positive for GBS. Specimens that were positive on culture were collected from the rectum (four of five specimens), urine (three of five), gastric aspirate (three of five), nares (two of five), and external auditory canal (two of five).
The urine of only one infant was positive by antigen testing. The Wellcogen, Bactigen, Directigen, and ICON assays were all positive after concentration of the urine eight times, while the Bactigen, Directigen, and ICON assays were also positive when the unconcentrated urine specimen was tested. This infant's ear, nares, gastric aspirate and rectal cultures were all positive for GBS, and his urine culture contained 10 4 to 10 5 CFU of GBS per ml. Repeat antigen testing and urine culture were negative at 48 h. The initial complete blood cell count was normal and the blood culture was sterile, and the patient was discharged from the nursery without antibiotic therapy at 72 h of life. Bacterial culture of the urine specimens produced 35 isolates from 32 other patients. These isolates included Escherichia coli (n ϭ 20), coagulase-negative staphylococcus (n ϭ 8), GBS (n ϭ 2), Enterococcus spp. (n ϭ 3), Micrococcus sp. (n ϭ 1), and Lactobacillus sp. (n ϭ 1). None of these urine cultures produced any false-positive urine antigen tests. Therefore, given the one uninfected patient with positive urine antigen assays, the specificities of these tests for detecting invasive GBS disease in neonates were 99.5% (219 of 220) for the Bactigen, Directigen, and ICON assays with either concentrated or unconcentrated urine and for the Wellcogen assay with concentrated urine. The Wellcogen assay was 100% specific with unconcentrated urine in the present study.
DISCUSSION
Numerous studies have supported the use of urine antigen assays in the rapid diagnosis of GBS sepsis in newborns because of the high degree of sensitivity of these assays. The use of an LPA assay specific for the GBS polysaccharide antigen was first reported by Edwards et al. (10) in 1979. Antigen was detectable by LPA in all cerebrospinal fluid specimens obtained on admission from 12 infants with type III GBS meningitis (10). Bromberger et al. (9) in 1980 detected GBS antigen in the concentrated urine of all 11 patients with GBS bacteremia. Webb and Baker (26) found the Streptex latex test kit, the first commercially available latex reagent, to be 93.3% sensitive in detecting GBS antigen in the concentrated urine of 15 patients with GBS meningitis.
The Wellcogen Strep B latex agglutination assay has been the most extensively studied of the available LPA assays. Ingram et al. (17) , using the Wellcogen Strep B latex agglutination assay, found urine to be the best source of GBS antigen.
Fifteen of 17 (88%) patients with early-onset GBS disease who were tested within the first 48 h of life had detectable antigenuria (17). Baker and Rench (4) (11) found a sensitivity of 90% (19 of 21) for the Wellcogen Strep B latex assay when initial concentrated urine samples were tested; the sensitivity improved to 100% when repeat samples collected within 12 h of presentation were included.
Rench et al. (23) evaluated the Directigen Group B Strep Test Kit, which initially used a murine monoclonal antibody to the GBS antigen as the active component, in a study of 19 infants with culture-proven GBS sepsis or meningitis. The LPA assay was positive for all seven infants whose concentrated urine was tested and 14 of 18 (78%) of the unconcentrated urine samples. The currently available Directigen assay uses a rabbit polyclonal anti-GBS latex reagent similar to those used in the other LPA assays. In another study with clinical specimens from newborns with GBS bacteremia, this assay was positive for all four specimens of concentrated urine (7) .
The ICON STREP B Assay, an enzyme immunoassay, has recently been marketed for the detection of GBS antigen in the urine of newborns (20) . This new assay is easy to use and is more rapid than LPA assays if it is used on unconcentrated urine, as recommended by the manufacturer in the package insert. The ICON STREP B Assay was 100% sensitive in the detection of GBS antigen in 35 unconcentrated urine samples when compared with the sensitivities of the Bactigen Group B Streptococcus LPA assay and blood culture (20) .
Recent reports have noted a much lower degree of sensitivity for the LPA assays. Becker et al. (6) , in a large multicenter study of neonates with GBS bacteremia, found a sensitivity of only 54% (38 of 71) for urine LPA assays. They also found that the sensitivity correlated with the severity of disease (6) . The Wellcogen Strep B assay was positive for only 4 of 15 (27%) neonates with culture-proven systemic GBS disease in a study by Hachey and Wiswell (14) . Both of those studies (6, 14) used primarily unconcentrated urine specimens, unlike the earlier studies.
Only one study has compared the sensitivities of the three commercially available GBS latex agglutination assays in vitro. Ascher et al. (1) found significant differences in sensitivity among the three assays when testing normal saline to which group-and type-specific antigens were added and urine and serum to which group-specific antigen was added. Overall, the Wellcogen assay had the lowest degree of sensitivity when it was compared with those of the Bactigen and Directigen assays a All assays were significantly different from each other in the ability to detect antigen. Analysis of variance for repeated measures, P ϭ 0.0001. Scheffé post hoc F test for multiple comparisons, P Ͻ 0.05.
(1). However, clinical specimens from infants with invasive GBS disease were not used in their study. This is the first published study to directly compare the three LPA assays and the new enzyme immunoassay in tests with clinical urine samples from infants with GBS bacteremia. With either concentrated or unconcentrated urine, the Wellcogen assay detected antigen in significantly fewer urine samples than the other assays did. This result is consistent with the findings of the previous in vitro study (1) . Although the manufacturer of the ICON assay does not specifically recommend concentration of the urine, we found that this immunoassay was significantly less sensitive than the Bactigen and Directigen assays when we tested unconcentrated urine. The ICON assay was as sensitive as the Bactigen and Directigen assays with concentrated urine. There were no significant differences in sensitivity between the Bactigen and Directigen assays, although the Directigen assay was able to detect antigen in higher dilutions of urine than the Bactigen assay was.
Many of the original studies evaluating the sensitivities of the LPA tests used concentrated urine as the preferred body fluid for evaluation (4, 7, 9, 11, 15, 17, 23, 26) . When compared directly, the testing of concentrated urine was more sensitive than that of unconcentrated urine in those studies (9, 11, 23, 25) . However, in clinical practice urine is frequently not concentrated prior to testing (6) , despite the recommendations of several of the manufacturers, probably because of the added cost and time required. In the present study, all four assays were significantly more sensitive when urine was concentrated prior to testing. Failure to concentrate the urine before testing may be responsible for the unusually low level of sensitivity noted in recent reports (6, 14) . These data indicate that clinicians who use urine antigen tests as part of an evaluation for sepsis in neonates should ensure that an adequate volume of urine is obtained and that the urine is concentrated prior to testing.
In the present study urine samples were obtained from the patients with positive blood cultures serially throughout the hospital stay and frequently after discharge. Despite adequate antibiotic therapy, antigenuria persisted in eight of the nine patients in whom antigen was detectable in their urine. One patient had antigenuria for 120 days, and a second patient had antigenuria for 33 days, despite negative serial blood and urine cultures and without any evidence of persistent GBS infection. Persistent antigenuria despite standard antibiotic therapy has been reported only twice. Seven of 10 patients for whom repeat urine samples were tested were antigen positive at the end of the 2-week course of therapy and one remained positive at 5 months in a study by Friedman et al. (11) . Baker et al. (5) reported a mean duration of antigenuria of 5.2 days in patients with bacteremia, with a range of 1 to 30 days, using countercurrent immunoelectrophoresis. Serial antigen testing of infants with GBS bacteremia cannot be used as a method of monitoring a patient's response to antibiotic therapy. Antigen assays may also not be useful in the evaluation of a neonate for subsequent episodes of suspected sepsis if the patient was previously bacteremic and antigenuric unless antigen tests with adequate sensitivity have been negative in the interval between infections.
The etiology of the persistent antigenuria seen in these patients is unknown. For the patient with antigenuria for 120 days, several rectal specimen cultures were positive for GBS (on days 120, 149, and 172). Low-grade absorption of GBS antigen from the gastrointestinal tract may have been responsible for the persistent antigenuria seen in this patient (2) . It is possible that some infants with asymptomatic colonization of the gastrointestinal tract but without invasive disease may excrete antigen in their urine, producing false-positive tests (2) , but the present study was not designed to evaluate that question.
The present study was limited by the small number of bacteremic patients included. However, a total of 90 individual urine samples collected from the nine patients with documented antigenuria were used in direct comparisons among the individual assays. The use of multiple urine samples from each patient allowed us to fully explore the differences in antigen detection among the assays, since these samples represent various amounts of antigen in urine.
The sensitivities of the urine antigen tests noted in this report differ from those noted in reports of previous studies and are lower than those seen in clinical practice, since serial samples collected at times remote from the onset of infection were included. It was not the intent of the present study to establish the sensitivities of these assays by using only the initial urine sample collected when the patients were first evaluated for infection, but rather to determine the differences in antigen detection among the commercially available brands of assays. Had only the initial concentrated urine samples collected within the first 48 h after birth been used for comparison, the Directigen assay would have had a sensitivity of 100% and the Wellcogen, Bactigen, and ICON assays would each have had a sensitivity of 86%. However, all patients may not have had such high concentrations of antigen present in their urine when they were initially evaluated (11) . There is a wide range of antigenuria seen clinically, with severely infected patients having more detectable antigen than mildly affected patients (6) . The amount of antigen present in all of our samples covers a very wide range (e.g., 1:1 to 1:512 for the Directigen assay). The variability in antigen load in the urine samples used in the present study may reflect the wide degree of variability in antigen load seen in clinical practice.
The urine specimens from two patients with bacteremia were classified as negative because of the elapsed time between the documentation of bacteremia and the collection of the urine sample, with a lack of any detectable antigen in the urine by any of the four assays. It is possible that these urine samples did contain GBS antigen in an amount below the level of detection of any of the four assays. Inclusion of these specimens in the analysis, however, would not have changed the significance of our results. Finally, the rationale for testing urine for GBS antigen 1 or 2 months after the onset of symptoms may be questioned as not being clinically relevant. It was not our intent to suggest that these assays would be useful so late after the onset of infection, but rather to evaluate the abilities of certain assays to detect concentrations of GBS antigen lower than those detected by other commercially available assays.
We did not detect any significant differences in specificity between the four assays. Only one patient in our study had a false-positive antigen test result, and cultures of both urine and rectal specimens from this patient were positive for GBS. This finding supports the conclusion of Sanchez et al. (24) that contamination of urine specimen bags with rectal and perineal colonizations may produce positive urine antigen tests in patients without invasive GBS disease (24) . Since the gastric aspirate culture from this patient was also positive for GBS, this patient's results are also consistent with the hypothesis of Ascher et al. (2) that gastrointestinal absorption of swallowed amniotic fluid contaminated with GBS may produce a falsepositive antigen test. However, the number of healthy infants colonized with GBS in our study (2.3%) was very low; our low rate of skin colonization may be responsible for our very low VOL. 33, 1995 ASSAYS FOR GROUP B STREPTOCOCCAL ANTIGEN 197 rate of false-positive antigen tests compared with those found in previous studies (4, 9, 11, 15, 17, 21) . Testing of urine for GBS antigen may be useful in the evaluation of neonates for suspected sepsis, especially if these infants receive antibiotic therapy before blood for culture is obtained or if they are born to mothers who receive antibiotics in the intrapartum period. We have demonstrated that the commercially available products differ in their abilities to detect GBS antigen in the urine of bacteremic newborns under the standardized conditions described. The sensitivities of these tests will be enhanced if the urine sample is concentrated prior to testing, regardless of the brand of assay chosen.
